In the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled Latitude PsO 3001 and 3002 studies, more than half of patients treated with zasocitinib achieved clear ...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI ...
ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as ...
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data ...
A woman suffered from plaque psoriasis, and various failed treatment options, for years. Now, after joining a clinical trial for ICOTYDE, an oral option for the chronic autoimmune condition, Amber ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. A Passion for Issues that Matter to Americans 50-Plus is All You ...
An itchy scalp could be a result of anything from dandruff to allergy to skin conditions like psoriasis. Here's how to get ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic ...
Johnson & Johnson has won U.S. Food and Drug Administration approval of its Icotyde treatment for certain patients with moderate-to-severe plaque psoriasis, a chronic autoimmune condition that causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results